Sticker shock
Ce dossier présente un ensemble d'articles concernant différents types d'immunothérapies dans le traitement des cancers (lymphocytes CAR-T, inhibiteurs de point de contrôle immunitaire ou vaccins) ainsi que le rôle du microbiome dans l'efficacité de ces traitements
Physician Peter Bach at Memorial Sloan Kettering Cancer Center is appalled at the sky-high price of cancer treatments in the United States, and he is watching new immune therapies drive them higher still. Checkpoint inhibitors for various solid tumors cost about $150,000 a year, and a personalized treatment called chimeric antigen receptor–T cell therapy tops out at $475,000. Dozens more immunotherapies are in clinical trials, as companies race to reap the monetary rewards. For the past decade, Bach has immersed himself in health policy and economics to decipher and publicize what's driving these high prices. Science spoke with Bach last month.
Science , commentaire, 2017